{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.1","value":"67.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"399"}],"units":"Participants"}],"title":"Cycle 2, day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.5","value":"95.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"341"}],"units":"Participants"}],"title":"Cycle 3, day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.9","value":"122"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"}],"units":"Participants"}],"title":"Cycle 4, day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.4","value":"159"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"}],"units":"Participants"}],"title":"Cycle 8, day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.7","value":"190"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"title":"Cycle 16, day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"98.7","value":"190"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"Cycle 24, day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.4","value":"223"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 32, day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"467"}],"units":"Participants"}],"description":"Cmin was measured for all participants that received at least one dose of Atezolizumab.","dispersionType":"Standard Deviation","groups":[{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG000","title":"Atezolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK-evaluable population is defined as patients who received atezolizumab treatment and had at least one measureable PK concentration.","reportingStatus":"POSTED","timeFrame":"Predose (0 hours) on Day 1 of Cycles 1, 2, 3, 4 and every 8 cycles thereafter; at treatment discontinuation (up to 25 months); at 120 days after last dose of atezolizumab (up to 25 months; each cycle is 21 days)","title":"Minimum Observed Serum Atezolizumab Concentration (Cmin)","type":"SECONDARY","unitOfMeasure":"mcg/mL"}